Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.32 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.32 |
| ▸ | AHR | P35869 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20199666 | 0.96 | SIRT2 (0.34) | KDM4EMEN1NPC1ALDH1A1MAPT | |
| SCHEMBL20696645 | 0.95 | SIRT2 (0.35) | KDM4EMEN1NPC1ALDH1A1MAPT | |
| SCHEMBL20199613 | 0.95 | SIRT2 (0.33) | KDM4EMEN1NPC1ALDH1A1MAPT | |
| SCHEMBL23739035 | 0.89 | SIRT2 (0.31) | SIRT2SIRT1 | |
| SCHEMBL23738819 | 0.87 | — | — | |
| SCHEMBL22617743 | 0.87 | SIRT2 (0.35) | KDM4EMAPTHPGDKMT2ASIRT2 | |
| SCHEMBL23738890 | 0.87 | SIRT2 (0.31) | SIRT2SIRT1 | |
| SCHEMBL20199720 | 0.86 | LMNA (0.30) | KDM4EMEN1ALDH1A1MAPTHPGD | |
| SCHEMBL20199761 | 0.86 | MEN1 (0.33) | KDM4EMEN1NPC1ALDH1A1MAPT | |
| SCHEMBL20199586 | 0.85 | KDM4E (0.37) | KDM4EMEN1NPC1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11001752-B2 | Double spiro organic compound and organic electronic element comprising same | LG CHEM, LTD. (KR) | 2021-05-11 | — | — | US | disclosed |
| US-20180148640-A1 | DOUBLE SPIRO ORGANIC COMPOUND AND ORGANIC ELECTRONIC ELEMENT COMPRISING SAME | LG CHEM, LTD. (KR) | 2018-05-31 | — | — | US | disclosed |
| US-20180148640-A1 | DOUBLE SPIRO ORGANIC COMPOUND AND ORGANIC ELECTRONIC ELEMENT COMPRISING SAME | LG CHEM, LTD. (KR) | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11001752-B2 | Double spiro organic compound and organic electronic element comprising same | DCX, TERT, TELO2 | KDM4E 1392/4885MEN1 2052/4885NPC1 3193/4885 |
| US-20180148640-A1 | DOUBLE SPIRO ORGANIC COMPOUND AND ORGANIC ELECTRONIC ELEMENT COMPRISING SAME | DCX, TERT, TELO2 | KDM4E 1392/4885MEN1 2052/4885NPC1 3193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.